Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2023-11-17 Declaration of Voting R…
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) held on November 17, 2023, by HLB Life Science. It explicitly lists the agenda item (approval of the spin-off plan) and the outcome (approved as proposed). This falls under the category of Declaration of Voting Results, as it reports the official outcome of shareholder voting at a general meeting.
2023-11-17 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for HLB Life Science Co., Ltd. covering the period from January 1, 2023, to September 30, 2023. It contains detailed company information, business descriptions, financial data, and management discussions, which are characteristic of a comprehensive interim financial report. It is not an announcement of a report (RPA) or a simple certification, but the report itself. 9M 2023
2023-11-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to disclose changes in their shareholdings or convertible securities. This falls under the category of Director's Dealing (DIRS), as it reports personal share/security transactions by a company executive (Cho Yong Ho).
2023-11-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership and call option status for HLB Co., Ltd. regarding its stake in HLB Life Science. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-11-14 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Supervisory Service and Korea Exchange regarding the issuance of convertible bonds (전환사채권 발행결정). This type of filing is a standard regulatory disclosure in the Korean market for capital structure changes, specifically debt financing that can be converted into equity. It details the terms, interest rates, conversion prices, and use of proceeds. According to the provided definitions, this falls under 'Capital/Financing Update' (CAP) as it relates to fundraising and financing activities.
2023-11-07 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from HLB Life Science regarding the acquisition of convertible bonds before maturity. It details the specific bond series, the amount acquired, the reason for acquisition (early redemption by agreement), and the method of disposal (cancellation). This falls under capital structure changes and financing activities, specifically related to debt management. Given the specific nature of the transaction (bond buyback/redemption), it fits best under the 'CAP' (Capital/Financing Update) category as it relates to the company's capital structure and debt obligations.
2023-11-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.